0001104659-23-034504.txt : 20230320 0001104659-23-034504.hdr.sgml : 20230320 20230320165254 ACCESSION NUMBER: 0001104659-23-034504 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230320 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230320 DATE AS OF CHANGE: 20230320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akoya Biosciences, Inc. CENTRAL INDEX KEY: 0001711933 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 475586242 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40344 FILM NUMBER: 23746885 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 BUSINESS PHONE: 855.896.8401 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 8-K 1 tm239970d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 20, 2023

Akoya Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-40344	47-5586242
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

100 Campus Drive, 6th Floor

Marlborough, MA
(Address of principal executive offices)

01752
(Zip Code)

(855) 896-8401

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, par value $0.00001 per share		AKYA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 20, 2023, Akoya Biosciences, Inc. (the “Company”) announced that Joseph Driscoll is retiring from his position as Chief Financial Officer of the Company, effective March 20, 2023. Mr. Driscoll will continue as a consultant for the Company in order to facilitate the transition of the Company’s new Chief Financial Officer.

On March 20, 2023, the Company’s Board of Directors appointed Johnny Ek as Chief Financial Officer of the Company, effective immediately. Mr. Ek will also serve as the Company’s principal financial officer and principal accounting officer.

Prior to joining the Company, Mr. Ek, age 47, was the Chief Financial Officer of Specific Diagnostics, Inc., a producer of a rapid antimicrobial susceptibility test, from August 2021 until its acquisition by bioMérieux SA (Euronext: BIM), a French multinational biotechnology company, in May 2022 and served as Chief Financial Officer of the Specific Diagnostics business following the acquisition until March 2023. From February 2019 until its acquisition by Roche Holding AG in August 2021, he served as Chief Financial Officer of GenMark Diagnostics, Inc. (formerly Nasdaq: GNMK), a provider of multiplex molecular diagnostic solutions. Prior to serving as GenMark’s Chief Financial Officer, Mr. Ek served as GenMark’s Vice President, Finance and Accounting and Corporate Controller from November 2013 to February 2019. Prior to that, Mr. Ek served as Vice President and International Controller for Affymetrix, Inc., a leading provider of cellular and genetic analysis products, from May 2013 to November 2013 and as Controller of eBioscience, Inc., a privately held provider of flow cytometry and immunoassay reagents, from October 2010 through eBioscience’s acquisition by Affymetrix in May 2013. Prior to joining eBioscience, Mr. Ek held various roles with Ernst & Young LLP from May 2001 to October 2010. Mr. Ek is a licensed Certified Public Accountant, and holds a B.S. in finance from Brigham Young University and a Master’s degree in accountancy from the University of Notre Dame’s Mendoza College of Business.

In connection with his appointment as Chief Financial Officer, Mr. Ek has entered into an employment offer letter with the Company that provides for an annual salary of $400,000 per year and a target bonus equal to 50% of his base salary. Mr. Ek will also receive a restricted stock unit award representing 160,000 shares of the Company’s common stock, which vests in four equal annual installments beginning on April 1, 2024. In addition, Mr. Ek will receive a stock option award to purchase 160,000 shares of the Company’s common stock, with the stock option award vesting 25% on April 1, 2024 and 1/48th of the stock option award vesting each month for the next 36 months thereafter. Mr. Ek will also become a party to the Company’s Executive Severance Plan, the terms of which are described in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on April 19, 2022.

There is no arrangement or understanding with any person pursuant to which Mr. Ek was appointed as Chief Financial Officer, and there are no family relationships between Mr. Ek and any director or executive officer of the Company. Additionally, there are no transactions between Mr. Ek and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On March 20, 2023, the Company issued a press release announcing the retirement of Mr. Driscoll and the appointment of Mr. Ek as Chief Financial Officer.

A copy of the press release is furnished as Exhibit 99.1, and the information set forth therein is incorporated herein by reference.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibits

99.1		Press Release, dated March 20, 2023
104		Cover Page Interactive Data File (formatted as Inline XBRL)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 20, 2023	Akoya Biosciences, Inc.

	By:	/s/ Brian McKelligon
		Brian McKelligon
		Chief Executive Officer

3

EX-99.1 2 tm239970d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Akoya Biosciences Announces Leadership Transition

Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer

Johnny Ek Appointed as new Chief Financial Officer

MARLBOROUGH, Mass., Mar. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company’s new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant for the company as Akoya executes a seamless transition between the two leaders.

Mr. Driscoll joined Akoya in April 2019 and has overseen the company’s financial performance both before and after the company went public in April 2021.

“I deeply value the opportunity I’ve had at Akoya to build a strong organization and support the company’s incredible trajectory over the last four years,” said Mr. Driscoll. “The company has established a strong foundation for continued high growth and I look forward to supporting the transition of responsibilities to Johnny as Akoya enters its next phase of growth.”

“On behalf of the Board and our team, I’d like to extend my sincere gratitude to Joe for his profound contributions to Akoya,” said Brian McKelligon, CEO of Akoya. “He played a pivotal and central role in driving our success and on behalf of all my fellow Akoyans I would like to thank Joe for all he has done for the company. We’re excited to welcome Johnny to the Akoya leadership team. His extensive experience from the research to the diagnostics markets will support our continued growth across all market segments, delivering value to customers and our shareholders.”

Johnny Ek has more than 20 years of financial leadership experience across the diagnostics and life sciences tools industries. He joins Akoya from Specific Diagnostics (acquired by bioMérieux in May 2022) where he served as Chief Financial Officer since August 2021. Prior to that, he served as Chief Financial Officer at GenMark Diagnostics, a provider of multiplex molecular diagnostic solutions, from February 2019 until August 2021 and oversaw the sale to Roche Diagnostics in March 2021. Prior to serving as GenMark’s Chief Financial Officer, Mr. Ek served as GenMark’s Vice President, Finance and Controller from 2013 to 2019 and prior to that as Vice President, Finance and Controller for Affymetrix from 2010 to 2013.

“Spatial biology is poised to change the practice of medicine and the field of discovery biology. Akoya is uniquely positioned to capitalize on this opportunity with its market leading technology, a talented team, and a strong ecosystem of customers and partners,” said Mr. Ek. “I look forward to stepping into this new role helping lead Akoya on this next phase of its journey.”

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About Akoya Biosciences

As The Spatial Biology Company^®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler^®, PhenoImager^® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com

EX-101.SCH 3 akya-20230320.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 akya-20230320_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 akya-20230320_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 20, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 20, 2023
Entity File Number	001-40344
Entity Registrant Name	Akoya Biosciences, Inc.
Entity Central Index Key	0001711933
Entity Tax Identification Number	47-5586242
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	100 Campus Drive
Entity Address, Address Line Two	6th Floor
Entity Address, City or Town	Marlborough
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01752
City Area Code	855
Local Phone Number	896-8401
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, par value $0.00001 per share
Trading Symbol	AKYA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 7 tm239970d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001711933 2023-03-20 2023-03-20 iso4217:USD shares iso4217:USD shares 0001711933 false 8-K 2023-03-20 Akoya Biosciences, Inc. DE 001-40344 47-5586242 100 Campus Drive 6th Floor Marlborough MA 01752 855 896-8401 false false false false Common stock, par value $0.00001 per share AKYA NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://akoyabio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm239970d1_8k.htm akya-20230320.xsd akya-20230320_lab.xml akya-20230320_pre.xml tm239970d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm239970d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm239970d1_8k.htm" ] }, "labelLink": { "local": [ "akya-20230320_lab.xml" ] }, "presentationLink": { "local": [ "akya-20230320_pre.xml" ] }, "schema": { "local": [ "akya-20230320.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "akya", "nsuri": "http://akoyabio.com/20230320", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm239970d1_8k.htm", "contextRef": "From2023-03-20to2023-03-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://akoyabio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm239970d1_8k.htm", "contextRef": "From2023-03-20to2023-03-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://akoyabio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-034504-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-034504-xbrl.zip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end